Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
28 February 2020Website:
http://www.passagebio.comNext earnings report:
07 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 20:58:17 GMTDividend
Analysts recommendations
Institutional Ownership
PASG Latest News
The heavy selling pressure might have exhausted for Passage Bio (PASG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Passage Bio (PASG) has been upgraded to a Zacks Rank #2 (Buy), indicating increasing confidence in the company's earnings potential. This could lead to a rise in the stock price in the short run.
Does Passage Bio, Inc. (PASG) have what it takes to be a top stock pick for momentum investors? Let's find out.
What type of business is Passage Bio?
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
What sector is Passage Bio in?
Passage Bio is in the Healthcare sector
What industry is Passage Bio in?
Passage Bio is in the Biotechnology industry
What country is Passage Bio from?
Passage Bio is headquartered in United States
When did Passage Bio go public?
Passage Bio initial public offering (IPO) was on 28 February 2020
What is Passage Bio website?
https://www.passagebio.com
Is Passage Bio in the S&P 500?
No, Passage Bio is not included in the S&P 500 index
Is Passage Bio in the NASDAQ 100?
No, Passage Bio is not included in the NASDAQ 100 index
Is Passage Bio in the Dow Jones?
No, Passage Bio is not included in the Dow Jones index
When does Passage Bio report earnings?
The next expected earnings date for Passage Bio is 07 August 2024